MedTrace Logo

Diagnostic and Prognostic Accuracy of FDHT-PET and Liquid Biopsies in Prostate Cancer

NCT05245435 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2023-03-20

No results posted yet for this study

Summary

Depending on the cohort of the study the diagnostic and prognostic accuracy and health economics considerations of \[18F\]-fluoro-5α-dihydrotestosterone (FDHT)- positron emission tomography (PET) and/or circulating tumor cells in prostate cancer patients are studied.

Conditions

Interventions

DIAGNOSTIC_TEST

FDHT-PET Scan

\[18F\]-fluoro-5α-dihydrotestosterone (FDHT)- positron emission tomography (PET)

DIAGNOSTIC_TEST

liquid biopsies

circulating tumor cell count and circulating tumor DNA abundance in blood of prostate cancer patients

Sponsors & Collaborators

  • Medical University of Vienna

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-30
Primary Completion
2024-09-30
Completion
2024-09-30

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05245435 on ClinicalTrials.gov